Post-Market Clinical Follow up Studies

by | Aug 23, 2019 | EU, Medical Devices, Regulatory, Requirements

Clinical evidence is required to assure the safety and efficacy of a medical device for intended use pre-market. After an appropriate risk-benefit analysis, the device may still be placed on the market with the residual risk. The questions about residual risk can be answered by conducting a post-market clinical study to assess the risk. A post-market clinical follow-up study is just one form of the many ways a company may decide to conduct post-market surveillance.

Circumstances that may result in the need for post-market clinical follow-up studies include, for example:1

  • Innovation, e.g., where the design of the device, the materials, the principles of operation, the technology or the medical indications are novel;
  • A new indication or claim has been approved;
  • Significant changes to device design or labeling;
  • Higher risk classification;
  • Higher risk anatomical locations;
  • The severity of disease/treatment challenges etc.

The elements of a post-market clinical follow-up study include:1

  • A clearly stated objective(s);
  • A scientifically sound design with an appropriate rationale and statistical analysis plan;
  • A study plan; and
  • Implementation of the study according to the plan, and analysis of the data and appropriate conclusion(s)

The study should be conducted in compliance with the plan, containing data analysis that draws conclusions on the residual risk, safety, and efficacy of the device by someone with appropriate expertise. Information concerning serious incidents identified during the study should be reported to the regulatory authorities.

The conclusions derived from the post-market clinical study may result in the need to open a CAPA, making changes to the labeling or IFU, changes to the manufacturing process, changes to the device design, etc.

A robust post-market surveillance program is a requirement set forth in the EU MDR. EMMA International can help you with all your EU MDR compliance needs.

Please refer to our EU MDR webpage:  Call us at 248-987-4497 or email us at

1GHTF (Feb 2010) Post-Market Clinical Follow-Up Studies retrieved on 08/21/2019 from


Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

Establishing a Culture of Compliance

Establishing a Culture of Compliance

While having robust compliance policies and procedures in place is essential for meeting regulatory requirements, it's equally important to establish a culture of compliance within your organization.  A culture of compliance means that every employee understands the importance of compliance and is committed to upholding it in all their work. Here are some tips for establishing a culture of compliance...
Change Management And Control

Change Management And Control

One of the biggest and most important aspects of quality management is a system to monitor changes and how they impact the product. Change management is an approach for changing processes or products in a way which adheres to regulatory standards by ensuring stability and consistency throughout processes. It applies across all changes within a process and throughout an entire products life cycle.
Aseptic Technique and Gowning

Aseptic Technique and Gowning

One of the most common techniques to prevent contamination of products and reduce quality impacts in the pharmaceutical industry is called aseptic gowning. Humans are the biggest sources of microbial contamination in cleanroom environments and therefore proper gowning procedures are essential to ensuring product quality. Proper training, education, hygiene, qualification, and authorization must be put in place and be required for entry to all clean room environments...

Ready to learn more about working with us?

Pin It on Pinterest

Share This